<DOC>
	<DOCNO>NCT02915198</DOCNO>
	<brief_summary>This research help u learn medicine call metformin reduces risk death , heart attack , and/or stroke patient pre-diabetes heart blood vessel problem .</brief_summary>
	<brief_title>Investigation Metformin Pre-Diabetes Atherosclerotic Cardiovascular OuTcomes</brief_title>
	<detailed_description>CSP # 2002 multicenter , prospective , randomize , double blind , secondary prevention trial test hypothesis treatment metformin , compare placebo , reduce mortality cardiovascular morbidity patient pre-diabetes establish atherosclerotic cardiovascular disease . Qualifying patient pre-diabetes define HbA1c , fast blood glucose , and/or oral glucose tolerance test criterion ; clinically evident coronary , cerebrovascular , peripheral arterial atherosclerotic cardiovascular disease ; estimate glomerular filtration rate least 45 mL/min/1.73 m2 ; fulfill exclusion criterion . Patients eligible agree participate randomly assign treatment metformin XR ( titrate maximum dose 2000 mg daily base safety tolerability ) match placebo . All patient receive counsel therapeutic lifestyle recommendation .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Prediabetes : This condition fulfil HbA1c least 5.7 % , le 6.5 % ; two measurement fast blood glucose ( separate day ) 100125 mg/dL ; 2hour blood glucose level 140199 mg/dL follow 75 g glucose load oral glucose tolerance test . These criterion must meet absence diabetic treatment . For participant qualify prediabetes basis HbA1c oral glucose tolerance testing , result must obtain within 5 month prior date screen visit , ensure data 6 month prior randomization . If HbA1c measure time period , average value least 5.7 % , le 6.5 % , determine qualification . To qualify prediabetes basis two fast blood glucose level 100125 mg/dL , test must perform period begin screen visit prior randomization visit , documentation fasting ( caloric intake ) least 8 hour prior blood sampling . To qualify prediabetes basis two fast blood glucose level 100125 mg/dL , test must perform period begin screen visit prior randomization visit , documentation fasting ( caloric intake ) least 8 hour prior blood sample . Any qualify laboratory value may obtain either VA nonVA laboratory , either case laboratory source document , include date ( ) test test result must available data record appropriate case report form 2 . Established atherosclerotic cardiovascular disease : Qualifying participant must evidence atherosclerotic disease least one follow vascular bed : coronary , cerebrovascular , peripheral arterial circulation . 1 . Coronary artery disease : Fulfilled least one ( 1 ) , ( 2 ) , ( 3 ) : 1 . History myocardial infarction least one month prior randomization : Fulfilled ( ) , ( b ) , : 1 . Hospital summary note record diagnosis myocardial infarction 2 . At least two follow : ) pathologic Qwaves ( and/or pathologic R wave lead V1 ) consistent myocardial infarction ; ii ) myocardial perfusion abnormality consistent infarction ; iii ) regional wall motion abnormality consistent infarction . ( 2 ) History percutaneous coronary intervention coronary artery bypass surgery least one month prior randomization ( 3 ) Angiographic evidence significant coronary stenosis : At least 50 % luminal stenosis least 2 major epicardial vessel ( left main , leave anterior descending , leave circumflex , right coronary artery ) . b ) Cerebrovascular disease : Fulfilled least one criterion ( 1 ) ( 4 ) : ( 1 ) Documented prior ischemic stroke ( least one month prior randomization ) base upon least one following : 1. stroke document hospital discharge summary neurologic consultation note , include subarachnoid subdural hemorrhage ; 2. neuroimaging study consistent prior ischemic stroke ( 2 ) Carotid artery stenosis 50 % history transient ischemic attack transient ischemic visual symptom attributable identified lesion ( ) ( 3 ) Asymptomatic carotid stenosis 70 % ( 4 ) History carotid revascularization ( surgical catheterbased ) c ) Peripheral arterial disease : Fulfilled ( 1 ) , ( 2 ) , : 1 . History aortoiliac peripheral artery intervention ( surgical catheter base ) amputation limb ischemia 2 . Symptoms intermittent claudication ankle : brachial index 0.85 3.Renal function : Estimated glomerular filtration rate ( MDRD formula ) least 45 mL/min/1.73 m2 . 4.Informed consent provide , participant agrees study procedure . 1 . Related metabolic state : 1 . Current treatment antidiabetic medication 2 . Treatment systemic glucocorticoid within 3 month randomization ( due potential effect blood glucose HbA1c level ) . 3 . Screening fast blood glucose 140 mg/dL HbA1c 7.0 % , nonfasting blood glucose 200/mg/dL record within past year . 2 . Related safety , tolerability , previous treatment metformin : 1 . Metabolic acidosis ( total CO2 local laboratory lower limit normal recent blood chemistry panel ) 2 . Cirrhosis , active hepatitis , jaundice time randomization , total bilirubin &gt; 2 time upper limit normal recent ( screen ) laboratory study 3 . Binge heavy alcohol consumption within past 6 month . Binge drinking define consumption 5 alcoholic drink men 4 woman within 2 hour . Heavy drinking define consumption 5 alcoholic drink one occasion , occur 5 time month . 4 . Severe anemia ( &lt; 10 g/dL ) time randomization 5 . Prior history intolerance metformin 6 . Treatment metformin within precede year 3 . Related likelihood nonmodifiable event : 1 . Uncontrolled hypertension ( systolic blood pressure 180 mm Hg diastolic blood pressure 110 mm Hg randomization visit , despite treatment 2 . New York Heart Association Class IIIIV congestive heart failure symptom randomization visit , despite treatment 4 . Related prognosis , reliability , ethic , data validity : 1 . Expected survival less study duration 2 . Persons consider unable , unwilling , unreliable meet protocol requirement 3 . Impaired decisionmaking capacity , define history dementia cognitive impairment 4 . Concurrent participation another research study evaluate drug device treatment . 5 . Female participant 1 . Pregnant intent become pregnant trial 2 . Lactating 3 . Women childbearing potential use highly effective method contraception specify Operations Manual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Prediabetic State</keyword>
	<keyword>Hemoglobin A , Glycosylated</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
</DOC>